January 26, 2021

Volume XI, Number 26

Advertisement

January 25, 2021

Subscribe to Latest Legal News and Analysis

Health Care Enforcement in 2016: A Look Back on 2015 and Forecasting the Year Ahead

2015 was a year of transition for the U.S. Department of Justice (“DOJ”), with the installation of a new Attorney General, Deputy Attorney General, and several other high-level officials. In January 2015, Andrew Weissmann came on board as Chief of the Fraud Section, filling a key role within DOJ’s Criminal Division, and reuniting the leadership of the Enron Task Force. (The task force initially had Leslie R. Caldwell, the current Assistant Attorney General in charge of the Criminal Division, and Mr. Weissmann at its helm). In March 2015, Benjamin R. Mizer became Principal Deputy Assistant Attorney General and Acting Assistant Attorney General in charge of the Civil Division. The reorganization was completed with the installation of Sally Quillian Yates as Deputy Attorney General and, finally, of Loretta E. Lynch as Attorney General, this past spring.

Despite the many officials in transition and the other important law enforcement challenges that the government faced in 2015, based on the cases pursued by DOJ and its partners, health care fraud remains a top enforcement priority. Moreover, there have been policy developments that will impact health care fraud enforcement, as will, we anticipate, DOJ’s new compliance counsel.

On September 9, 2015, DOJ Deputy Attorney General Yates issued a memo reaffirming the government’s commitment to investigating individuals and prosecuting culpable ones, as well as formally directing its prosecutors to prioritize individual accountability when addressing corporate misconduct. Since then, there has been a lively debate regarding the significance of this development and whether it actually represents a change in policy. Time, of course, will be the best judge. In the meantime, here are the basics from the memo, as well as some additional commentary by high-level DOJ officials.

Read the rest of the review here.

Advertisement
©1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume VI, Number 6
Advertisement

TRENDING LEGAL ANALYSIS

Advertisement
Advertisement

About this Author

Hope S. Foster, Member. Chair, Health Care Enforcement Defense Practice,Life Sciences Laboratories Diagnostics Hospitals & Health Systems
Member / Chair, Health Care Enforcement Defense Practice

Hope has a national reputation as a health care enforcement defense lawyer and chairs the firm’s Health Care Enforcement Practice. She regularly defends health care companies in governmental investigations and ensuing cases, conducts internal investigations, and advises health care providers and manufacturers regarding enforcement issues. She has in-depth knowledge of laboratory regulations. Many of Hope’s engagements are the result of qui tam cases initiated by whistleblowers under federal and state false claims acts. She often works with companies to develop and implement policies and...

202-661-8758
Laurence J. Freedman, Litigation Attorney, Mintz, Enforcement Defense Law
Member

Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by...

202-434-7372
Advertisement
Advertisement